公开(公告)号：US20240344140A1

公开(公告)日：2024-10-17

申请号：US18594650

申请日：2024-03-04

Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Inventor： Hongzhi Zou ,  David Ahlquist ,  Jonathan J. Harrington

IPC: C12Q1/6886 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  G01N33/57419 ,  C12Q2600/154 ,  C12Q2600/156 ,  G01N2333/805 ,  G01N2800/50 ,  G01N2800/7028

Abstract: The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor associated gene alterations, tumor associated proteins) and blood markers (e.g., hemoglobin, serum proteins) in a stool sample obtained from the mammal.

公开(公告)号：US20240207202A1

公开(公告)日：2024-06-27

申请号：US18534114

申请日：2023-12-08

Applicant: The Wistar Institute of Anatomy and Biology

Inventor： Gao Zhang ,  Qin Liu ,  Dario Carlo Altieri ,  Meenhard Herlyn

IPC: A61K31/06 ,  A61K31/155 ,  A61K31/245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/713 ,  A61K45/06 ,  A61P35/00 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K31/06 ,  A61K31/155 ,  A61K31/245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C12Q1/6886 ,  G01N33/5743 ,  A61K31/713 ,  A61K2300/00 ,  C12Q2600/158 ,  G01N2800/44 ,  G01N2800/60 ,  G01N2800/7028

Abstract: Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

公开(公告)号：US11982675B2

公开(公告)日：2024-05-14

申请号：US16759422

申请日：2018-10-25

Applicant: CELLPHARMA KFT. ,  TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT

Inventor： Edit Szabó ,  Dóra Kovács-Türk ,  Ágnes Telbisz ,  Nóra Kucsma ,  Tamás Horváth ,  Gergely Szakács ,  László Homolya ,  Balázs Sarkadi ,  Várady György

IPC: C07K14/705 ,  C12P17/06 ,  G01N21/64 ,  G01N33/50 ,  G01N33/58 ,  G01N33/60

CPC classification number: G01N33/582 ,  C07K14/705 ,  C12P17/06 ,  G01N21/64 ,  G01N33/5035 ,  G01N33/60 ,  G01N2800/52 ,  G01N2800/7028

Abstract: ABC multidrug transporters are key players in cancer multidrug resistance and in general xenobiotic elimination, thus their functional assays provide important tools for research and diagnostic applications. It has been found that in cells expressing functional ABCG2, ABCB1, or ABCC1 transporters, cellular PG fluorescence is strongly reduced. The invention relates to methods and uses of fluorescein derivative ester compounds of formula Ia which are analogs of PG for assessing ABC transporter activity of ABC multidrug transporters. The present accumulation assay is a novel tool for the parallel determination of the function of the multidrug transporters, in particular ABCG2, ABCB1, and ABCC1. The assay is applicable for diagnostic purposes and also allows the selection, separation and culturing of selected cell populations expressing such transporters.

公开(公告)号：US11974730B2

公开(公告)日：2024-05-07

申请号：US16871987

申请日：2020-05-11

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO ,  THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Inventor： Glenn T. Furuta ,  Steven J. Ackerman

IPC: A61B1/273 ,  A61B1/00 ,  A61K31/437 ,  A61K31/4375 ,  C12Q1/04 ,  C12Q1/527 ,  C12Q1/6883 ,  G01N33/53 ,  G01N33/68

CPC classification number: A61B1/2733 ,  A61B1/00156 ,  A61K31/437 ,  A61K31/4375 ,  C12Q1/04 ,  C12Q1/527 ,  C12Q1/6883 ,  C12Y406/01002 ,  G01N33/5308 ,  G01N33/6863 ,  G01N33/6866 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/521 ,  G01N2333/988 ,  G01N2800/14 ,  G01N2800/7028 ,  G01N2800/7095 ,  Y02A90/10

Abstract: In some embodiment, the present invention is directed to a device for obtaining samples from a subject. In other embodiments, methods and devices of the present invention allow the evaluation of conditions of the gastrointestinal tract of a subject. Measurements may be utilized, for example, to diagnose a disease of the esophagus, to monitor inflammation of the esophagus, or to access the treatment of a disease of the esophagus. In one embodiment, the invention comprises a method for measuring esophageal inflammation comprising deploying a device into the esophagus of a subject, removing the device after a predetermined period of time, analyzing the device for a diagnostic indicator of esophageal inflammation and evaluating the diagnostic indicator to diagnose esophageal inflammation.

公开(公告)号：US11971409B2

公开(公告)日：2024-04-30

申请号：US16892642

申请日：2020-06-04

Applicant: Berkeley Lights, Inc.

Inventor： Kevin T. Chapman ,  Mark P. White ,  Xiaohua Wang ,  Minha Park ,  Guido K. Stadler ,  Randall D. Lowe, Jr. ,  Xiao Guan Radstrom ,  Jason M. McEwen ,  Gang F. Wang ,  George L. Fox ,  Peggy A. Radel

IPC: B01L3/00 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/543 ,  G01N33/569 ,  G01N33/574

CPC classification number: G01N33/574 ,  B01L3/502761 ,  C07K16/00 ,  C07K16/2887 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/54366 ,  G01N33/56972 ,  B01L2200/0647 ,  G01N2800/7028

Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

公开(公告)号：US11913959B2

公开(公告)日：2024-02-27

申请号：US17207412

申请日：2021-03-19

Applicant: Memorial Sloan Kettering Cancer Center

Inventor： Larry Norton ,  Ross Levine ,  Maria Kleppe ,  Elizabeth Comen

IPC: C12Q1/6886 ,  G01N33/574 ,  C07K16/28 ,  A61K31/7068 ,  A61K31/7052 ,  A61K31/52 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/506 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  A61K31/00

CPC classification number: G01N33/57484 ,  A61K31/506 ,  A61K31/52 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7068 ,  A61K38/177 ,  A61K39/3955 ,  A61K45/06 ,  C12Q1/6886 ,  G01N33/57496 ,  A61K31/00 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7028

Abstract: Provided herein are methods of treating a nonhematopoietic malignant tumor in a patient and methods of prognosing a nonhematopoietic malignant tumor in a patient, comprising administering to the patient a therapeutically effective amount of an agent that preferentially kills or inhibits proliferation or activity of leukocytes relative to nonhematopoietic cells.

公开(公告)号：US11802315B2

公开(公告)日：2023-10-31

申请号：US16633389

申请日：2018-08-09

Applicant: PamGene B.V. ,  Erasmus University Medical Center Rotterdam

Inventor： Robby Ruijtenbeek ,  Dirgje Maria Adriana Van Den Heuvel ,  Richard De Wijn ,  Joan Gertrudis Jacobus Victor Aerts ,  Adrianus Henricus Josephus Mathijssen

IPC: C12Q1/6886 ,  C12Q1/48

CPC classification number: C12Q1/6886 ,  C12Q1/485 ,  G01N2440/14 ,  G01N2800/52 ,  G01N2800/7028

Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with non-small-cell lung carcinoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non-small-cell lung carcinoma to specific medicaments. More specifically, the present invention provides methods which measure kinase-activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in blood samples of said patients.

公开(公告)号：US11760807B2

公开(公告)日：2023-09-19

申请号：US15309391

申请日：2015-05-08

Applicant: Chugai Seiyaku Kabushiki Kaisha ,  F. Hoffmann-La Roche AG

Inventor： Toshihiko Ohtomo ,  Takayoshi Tanaka ,  Yasuo Sugitani ,  Oscar Puig ,  Ruey-min Lee ,  Gong Chen ,  Anton Belousov ,  Ya-Chi Chen ,  Bernhard Reis

IPC: C07K16/30 ,  G01N33/574 ,  G01N33/50 ,  G01N33/53 ,  G01N33/569 ,  C12Q1/6886 ,  A61K39/00

CPC classification number: C07K16/303 ,  C12Q1/6886 ,  G01N33/5011 ,  G01N33/56972 ,  G01N33/57438 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/92 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/52 ,  G01N2800/7028

Abstract: A method is provided for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or for determining the continuation of GPC3-targeting drug therapy for a patient treated with GPC3-targeting therapy. The method includes determining the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of the immunocyte or the expression level of the molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. GPC3-targeting drugs and drug preparations for use according to the disclosed methods are also provided.

公开(公告)号：US20230258625A1

公开(公告)日：2023-08-17

申请号：US18137113

申请日：2023-04-20

Applicant: Peter Blume-Jensen

Inventor： Peter Blume-Jensen

IPC: G01N33/50

CPC classification number: G01N33/5041 ,  G01N2440/14 ,  G01N2800/7028

Abstract: The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

公开(公告)号：US20230248770A1

公开(公告)日：2023-08-10

申请号：US18170776

申请日：2023-02-17

Applicant: Gadeta B.V.

Inventor： Jurgen Herbert Ernst Kuball ,  Guido Joris Jan Kierkels ,  Zsolt Sebestyen

IPC: A61K35/17 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  G01N33/569 ,  C07K14/725 ,  A61P35/00 ,  C12N15/62 ,  C12N15/90 ,  C12Q1/6809

CPC classification number: A61K35/17 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  G01N33/56977 ,  C07K14/7051 ,  A61P35/00 ,  C12N15/62 ,  C12N15/907 ,  C12Q1/6809 ,  C07K2317/32 ,  G01N2800/7028 ,  A61K38/00

Abstract: Disclosed herein are compositions and methods of treating a subject with cancer. The compositions and methods utilize immunoresponsive cells to effect killing of tumor cells.